Futura Medical PLC

Futura Medical agrees joint venture to develop CBD product

“The benefits and applications of cannabis and cannabidiol in both the medical and consumer markets are well known and expanding rapidly," said Futura boss James Barder.

Futura Medical PLC -

Futura Medical PLC (LON:FUM) has agreed a joint venture with cannabis firm CBDerma Technology Limited to develop a skin-friendly cannabidiol (CBD) formulation.  

The joint venture will explore combining CBD with Futura’s DermaSys drug delivery system for the treatment of such symptoms as pain relief.

DermaSys provides targeted delivery of pharmaceutical ingredients through the skin.

Futura expects initial development costs of about US$1mln. But it said it does not see the project having any material impact on cashflow as its financial share of the project will be covered by existing resources.

"Futura's core strength lies in our research and development capabilities, particularly in the application of our proprietary Dermasys transdermal delivery system which enables targeted and controlled delivery of drugs through the skin,” said Futura chief executive James Barder.

“The benefits and applications of cannabis and cannabidiol in both the medical and consumer markets are well known and expanding rapidly.

“However, optimised and targeted topical delivery of the active ingredients remains a problem. We believe that our Dermasys technology has the potential to solve these issues, advancing product development and expanding indications and use of cannabidiol."

Futura shares were up 5% to 43.45p on Tuesday morning. 

-- Adds share price --

Quick facts: Futura Medical PLC

Price: £0.32

Market: AIM
Market Cap: £65.49 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Futura Medical PLC named herein, including the promotion by the Company of Futura Medical PLC in any Content on the Site, the Company receives...



Futura Medical's James Barder looking forward to headline data on lead drug...

Futura Medical PLC (LON:FUM) chief executive James Barder caught up with Proactive London's Andrew Scott to talk through the firm's interim results. He says the company’s team is speaking to key opinion leaders in the field of erectile dysfunction ahead of publishing headline data on lead...

1 week, 1 day ago

2 min read